Skip to content
MARKETS / NASDAQ / KZIA
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Kazia Therapeutics Ltd. KZIA

10 fiscal years on record · AUD · FY2024 reported · SEC filings only
AUD 42,000
▼ 98.2% YoY
AUD -20.7M
In brief

What this company does

The Company’s ADSs, each representing five-hundred Ordinary Shares, trade on the Nasdaq Capital Market under the symbol ‘KZIA’. The ongoing principal business of the Company has been pharmaceutical drug development. Kazia’s lead program is Paxalisib, (formerly known as GDC-0084), an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, that was specifically designed to treat brain cancer. Paxalisib was developed by Genentech, Inc (South San Francisco, California) and the company entered into a worldwide exclusive license for the asset in October 2016. Kazia is also developing EVT801, a small-molecule selective inhibitor of VEGFR3. EVT801 was originally discovered by Sanofi SA and was licensed to Evotec SE as part of a broader transaction.

Written from the business description in Kazia Therapeutics Limited's annual report to the U.S. Securities and Exchange Commission, filed 7 November 2025. Every sentence was checked against that document before publication.

Growth
AUD 42,000.00
Revenue, FY2024 · full 10-year series below
Revenue AUD M Net income AUD M
FY2024 · Revenue 0.0 · Net income -20.7
8M-10M-20M2015201620172018201920202021202220232024
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−49290 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Net -49290.5%
-20000%-40000%2015201620172018201920202021202220232024
ROE
FY2023 · ROE -2634.3%
-1000%-2000%2015201620172018201920202021202220232024

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow AUD M
FY2016 · FCF -11.4
-5M-10M2015201620172018201920202021202220232024

Total assetsAUD 6.1M
EquityAUD -8.3M
CashAUD 4.3M
Current ratio0.35×

Equity funds -137% of total assets.

The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · AUD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2024202320222021202020192018201720162015
Revenue AUD B0.00.00.00.00.0··0.00.00.0
Operating income AUD B··········
EBITDA AUD B··········
Income tax AUD B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0·
Net income AUD B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow AUD B········−0.0−0.0
EPS, diluted AUD −0.04−0.10−0.11−0.19−0.07−0.17−17.86−12.48−2.28−2.82
Dividend / sh AUD ··········
Payout %··········
ROE %·−2634.3−135.0−89.1−32.4−88.0−61.4−27.1−42.1·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Provenance
Company facts, as filed
How we verify · 4 failures in 37 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 39 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente4 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code C3
Fiscal year endsJune 30
Data on record since2015

Share this section

Download image